May 20, 2015

FaegreBD Represents CoLucid Pharmaceuticals in $55M IPO

Faegre Baker Daniels represented Massachusetts-based CoLucid Pharmaceuticals, Inc. in its $55 million initial public offering. The IPO closed on May 11, and the company will now trade on the NASDAQ as CLCD.

CoLucid is a Phase 3 clinical-stage biopharmaceutical company that is developing an innovating and proprietary small molecule for the acute treatment of migraine headaches.

The FaegreBD team representing CoLucid included Dan Boeglin, Jon Zimmerman, Christine Long, Kassendra Galindo and Miranda Hirner, with support from John Haveman, Laura Yockey, Patrick Thornberry, Zachery Froelich, Lee Tumminello, Catherine Clements, George Martin, Lisa Pugh and Tracy Whitman.

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.